topstockalerts
Wells Fargo upgraded Zimmer Biomet Holdings to Overweight and established a $123 price target, citing improving growth prospects ahead of the launch of its Monogram robotic surgical system. Analyst Larry Biegelsen said Monogram addresses the main weakness in the company’s otherwise mid-single-digit growth portfolio: its knee business, which accounts for approximately 38% of sales and is expected to decline slightly in 2026.
The upcoming robotic system could help reverse that weakness by improving surgical precision and patient outcomes. Stifel also raised its price target to $140 from $125 while reiterating a Buy rating, following positive feedback from high-volume orthopedic surgeons at a healthcare conference. Physicians highlighted Monogram’s potential to reduce surgeons’ physical workload through automated bone cutting while improving procedural outcomes. Truist Securities likewise increased its target to $114.
$ZBH
